Syneron Medical Ltd.  

(Public, NASDAQ:ELOS)   Watch this stock  
Find more results for ELOS
6.78
-0.04 (-0.59%)
Real-time:   11:57AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.75 - 6.84
52 week 6.10 - 12.90
Open 6.84
Vol / Avg. 5,997.00/49,791.00
Mkt cap 232.27M
P/E     -
Div/yield     -
EPS -0.17
Shares 35.27M
Beta 1.14
Inst. own 75%
Jul 20, 2016
Q2 2016 Syneron Medical Ltd Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 19, 2016
Q1 2016 Syneron Medical Ltd Earnings Release - 9:30AM EDT - Add to calendar
May 19, 2016
Q1 2016 Syneron Medical Ltd Earnings Call - 8:30AM EDT - Add to calendar
Feb 22, 2016
Q4 2015 Syneron Medical Ltd Earnings Release
Feb 22, 2016
Q4 2015 Syneron Medical Ltd Earnings Call
Feb 11, 2016
Syneron Medical Ltd at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 2.50% -2.28%
Operating margin 2.56% -2.32%
EBITD margin - 2.30%
Return on average assets 2.79% -2.14%
Return on average equity 3.74% -2.90%
Employees 784 -
CDP Score - -

Address

Tavor Building 4 P.O. Box 550
YOKNEAM, 2069200
Israel
+972-7-32442200 (Phone)
+972-7-32442202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Syneron Medical Ltd. is engaged in manufacture, research, development, marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments. The Company's products targets an array of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, laser-assisted lipolysis and topical skin brightening products.

Officers and directors

Shimon Eckhouse Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Amit Meridor Chief Executive Officer
Bio & Compensation  - Reuters
Hugo Goldman Chief Financial Officer
Bio & Compensation  - Reuters
Erik Dowell Vice President-North America
Age: 43
Bio & Compensation  - Reuters
William Griffing Chief Executive Officer - Syneron Candela North America
Age: 48
Bio & Compensation  - Reuters
Shlomo Alkalay Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Robert Ruck Executive Vice President, Asia Pacific
Age: 54
Bio & Compensation  - Reuters
Robert Fielitz Vice President and Managing Director of Europe, Middle East and Africa
Age: 46
Bio & Compensation  - Reuters
Sarit Soccary Vice President-Strategy and Business Development
Age: 43
Bio & Compensation  - Reuters
Ilan Nacasch Chief Branding Officer
Age: 41
Bio & Compensation  - Reuters